Articles:

‘We aren’t aware of anyone doing it in this way before,’ says Johnston, ‘because anyone who could do the stakeholder piece couldn’t then design the DfMA systems and vice versa...’.

It should be the designers that are stitching all those bits together, understanding those standards, understanding what's available.That's a massive role.

It's a very interesting role,” he says..Still, Johnston acknowledges that the design community is currently meeting the idea of DfMA with more fear than excitement.. “The old cookie-cutter buildings get trotted out as a reason not to do DfMA,” he says.“There’s so much to get on with, there's so much to build.

There's so much opportunity in this space that designers should be seeing this as a phenomenal space to step into and an exciting place.But it doesn't feel like that's necessarily landing with the design community at the moment.”.

Marks describes the world of the “new possible,” where everyone becomes a productiser making products, where owners become true influencers, and where some, like the ‘super subs’, general contractors, and builders, become systems integrators.

In this space, she says, it is only the architects who become more fully what they’ve always been and always set out to be..During the most recent years he is been leading the early design development of a. new type of rehabilitative prison.

for the Ministry of Justice.. Steven also holds a Diploma in Advanced Studies in Multimedia Technology and Virtual Reality and prior to working at Bryden Wood gained five years of experience designing and implementing data-driven web applications.He is using the skills acquired in this field to standardise the approach to the briefing and decision making processes for architectural projects and develop an evidence-based approach to architectural design..

The most advanced implementation of this approach has been for GlaxoSmithKline.Together with Martin Wood, and John Dyson (Vice President Global Capital Projects) Steven has developed an approach, called the ‘Front End Factory’, that has been in use by GSK for about two years now to make high level strategic decisions about all their capital investments worldwide..